There is no commercial support for this activity.

About The Speaker

Dr. John F. Greden is the Rachel Upjohn Professor Emeritus of Psychiatry and Clinical Neurosciences in the Department of Psychiatry, Active Emeritus; Founder of the Frances and Kenneth Eisenberg and Family Depression Center and served as its executive director from 2001-21; Founding Chair, National Network of Depression Centers (NNDC); and Research Professor Emeritus in the Michigan Neurosciences Institute. He joined the faculty at the University of Michigan Medical School in 1974 and served as Chair of the University of Michigan’s Department of Psychiatry from 1985 to 2007, when he stepped down to focus on directing the Depression Center and developing the NNDC.

To address the globe’s huge health burdens, disabilities and costs associated with clinical depressions, bipolar disorders, and related conditions, Dr. Greden proposed establishment of the country’s inaugural Eisenberg Family Depression Center at the University of Michigan. Approved by the Regents in 2001, a new Depression Center-Ambulatory Psychiatry facility opened in 2006. The Eisenberg Family Depression Center integrates research, clinical, educational and public policy efforts of more than 330 members from 13 University Schools and Colleges and 33 different University departments. Dr. Greden subsequently led efforts to establish similar centers throughout the country and integrate them into a National Network of Depression Centers patterned after the National Cancer Center Network. 16 eminent universities signed an NNDC Charter in a ceremony in Ann Arbor in October, 2008 and the NNDC has now grown to 27. Dr. Greden served as the Chair of the National Network of Depression Centers from its foundation until 2014, and now serves as Founding Chair.

Dr. Greden is past-President of the Society of Biological Psychiatry; the Psychiatric Research Society; the American Association of Chairs of Departments of Psychiatry (AACDP); the Academic Psychiatry Consortium; and the Board of Directors of the American Foundation for Suicide Prevention. He edited the Journal of Psychiatric Research for seven years, chaired the Council on Research for the American Psychiatric Association for five years, served as Council Member of the American College of Neuropsychopharmacology (ACNP), Co-Chair of the National Psychiatry Training Council established by NIMH, and was selected as the 2005 recipient of the Distinguished Alumnus Award of the University of Minnesota Medical School. In  2013 the University of Michigan’s Council for Disability Concerns awarded Dr. Greden the James T. Neubacher Award. The American Psychiatric Association recently conveyed the Mrazek keynote Award to him for leading pharmacogenomic research efforts, and American College of Psychiatrists awarded the Mood Disorders Research Award and plenary speaker award for the 2021 meeting, and the Michigan Governor appointed him to a newly established Suicide Prevention Commission, where he serves on the Executive Committee.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

John F. Greden, M.D., reports having scientific advisory functions with Janssen Pharmaceutical, Naurex (Allergan) Pharmaceutical, Cerecor Pharmaceutical, NeuralStem, Med-IQ, Inc., College Student Mental Health ConsuSAGE Therapeutics, Pharmacogenomics Study Funded by AssureX and Myriad Neuroscience (I am not a paid consultant or employee), Clarigent (Artificial Intelligence for suicide prevention): pending ltant, during the past 12 months. He will discuss medications, and off-label uses in this presentation. This presentation was initially planned and recorded prior to January 1, 2023; therefore, the financial disclosure statement from the speaker reflects only the preceding 12 months, as was the standard at the time. This enduring activity was last reviewed for content validity on June 5, 2024. All conflicts have been mitigated through review.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Elizabeth Ryznar, MD, MSc, Louis J. Marino, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Stacey Garnett, RN, MSN, Stephanie M. Robinson, MSN, RN, PMH-BC, NPD-BC, NE-BC , Heather Billings, RN, Lisa Illum, MLIS, MEd, and Jennifer Tornabene.